Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Airway

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,312 result(s) found for: Airway. Displaying page 9 of 66.
    EudraCT Number: 2009-017772-25 Sponsor Protocol Number: CQVA149A2303 Start Date*: 2010-10-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A 26-week treatment multi-center, randomized, doubleblind, parallel-group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 μg q.d....
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) ES (Completed) FR (Completed) DE (Completed) GB (Completed) BG (Completed) NL (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2007-003189-16 Sponsor Protocol Number: CQMF149B2201 Start Date*: 2007-09-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, multi center, parallel group, double-blind, placebo and formoterol controlled 14 day dose ranging trial 4 doses of indacaterol delivered via Twisthaler®, in patients with COPD.
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) HU (Completed) BE (Completed) FR (Completed) LT (Completed) GB (Completed) IT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2013-001057-27 Sponsor Protocol Number: CCD-1207-PR-0091 Start Date*: 2014-01-24
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 52-week, double-blind, randomized, multinational, multicentre, 2-arm parallel-group, active-controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate p...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) HU (Completed) DE (Completed) IT (Completed) CZ (Completed) SK (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-000822-30 Sponsor Protocol Number: 205.346 Start Date*: 2006-10-25
    Sponsor Name:Boehringer Ingelheim Pharma GmbH
    Full Title: A randomized, double-blind, double-dummy, parallel group trial comparing 12 weeks treatment with tiotropium inhalation capsules 18 mcg via the HandiHaler® once daily to Combivent® Inhalation Aeroso...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD) including chronic bronchitis and emphysema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) LT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002873-21 Sponsor Protocol Number: RES100769 Start Date*: 2005-03-23
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A study to assess disease pathology and key therapeutic targets in severe asthma
    Medical condition: Mild to severe persistent asthma.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006736-22 Sponsor Protocol Number: NAF 03.4.05.033 Start Date*: 2007-02-14
    Sponsor Name:Netherlands Asthma Foundation (NAF) [...]
    1. Netherlands Asthma Foundation (NAF)
    2. Stichting astma bestrijding
    Full Title: An early diagnosis of asthma in young children by using non-invasive biomarkers of oxidative stress/airway inflammation, and early lung function measurements
    Medical condition: children with recurrent respiratory symptoms)
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2021-004248-11 Sponsor Protocol Number: Ahus-ATHENIAN Start Date*: 2021-11-10
    Sponsor Name:Akershus University Hospital
    Full Title: Antibiotic THErapy iN vIral Airway iNfections (ATHENIAN): An open labelled randomized controlled pragmatic trial to evaluate the efficacy and safety of discontinuing antibiotic therapy in adult pat...
    Medical condition: Patients with viral respiratory tract infection (influenza virus, parainfluenza virus, respiratory syncytial virus or human metapneumovirus)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012546-23 Sponsor Protocol Number: CCD-0906-PR-0016 Start Date*: 2009-10-02
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 48-WEEK, DOUBLE BLIND, RANDOMIZED, MULTINATIONAL, MULTICENTRE, 2-ARM PARALLEL GROUP, REFERENCE TREATMENT CONTROLLED CLINICAL TRIAL OF “FIXED COMBINATION” BECLOMETHASONE DIPROPIONATE PLUS FORMOTER...
    Medical condition: Severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) GB (Completed) CZ (Completed) AT (Completed) ES (Completed) FR (Completed) IT (Completed) HU (Completed) NL (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-002057-38 Sponsor Protocol Number: CQVA149A2339 Start Date*: 2012-08-16
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A placebo and active controlled study to assess the long-term safety of once daily QVA149 for 52 weeks in Chronic Obstructive Pulmonary Disease (COPD) patients with moderate to severe airflow limit...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) HU (Completed) GB (Completed) LV (Completed) EE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005146-23 Sponsor Protocol Number: CQAB149B2349 Start Date*: 2009-02-19
    Sponsor Name:Novartis Farmacéutica
    Full Title: Estudio multicéntrico, aleatorizado, doble ciego, doble enmascarado, con grupos paralelos de 12 semanas de tratamiento para evaluar la superioridad de indacaterol (150 µg o.d.) administrado mediant...
    Medical condition: EPOC (Enfermedad Pulmonar Obstructiva Cronica)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) SK (Completed) HU (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-004297-98 Sponsor Protocol Number: 117113 Start Date*: 2014-09-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study 117113: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level.
    Medical condition: Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) DE (Completed) GB (Completed) DK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-006796-21 Sponsor Protocol Number: D5892C00015 Start Date*: 2007-04-13
    Sponsor Name:AstraZeneca AB
    Full Title: A 12-week, double-blind, randomised, parallel group, multi-centre, study to evaluate efficacy and safety of budesonide/formoterol (Symbicort® Turbuhaler®) 320/9 µg one inhalation twice daily on top...
    Medical condition: Severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) ES (Completed) SE (Completed) DE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-004466-41 Sponsor Protocol Number: A6631011 Start Date*: 2008-02-26
    Sponsor Name:Pfizer Ltd, Ramsgate Road, Sandwich, Kent
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 (0.5, 3, 6 AND 10 MG) IN ADULTS WITH M...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) FR (Completed) GR (Completed) NL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-000210-15 Sponsor Protocol Number: ION-827359-CS2 Start Date*: 2020-10-08
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Patients with Mild to Moderate COPD with Chronic Bronchitis
    Medical condition: Mild to Moderate Chronic obstructive pulmonary disease (COPD) with Chronic Bronchitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004641-41 Sponsor Protocol Number: D3060C00003 Start Date*: 2012-02-10
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, double-blind, placebo-controlled, multi-centre, 6-way cross-over, single-dose Phase IIa study to investigate the local and systemic effects of 3 different doses of inhaled AZD2115 com...
    Medical condition: AZD2115 is being developed to treat chronic obstructive pulmonary disease (COPD).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-017380-42 Sponsor Protocol Number: M/34273/29 Start Date*: 2010-03-31
    Sponsor Name:ALMIRALL, S.A.
    Full Title: Efficacy and safety of three doses of aclidinium bromide compared to placebo and to an active comparator all administered twice daily by inhalation in patients with stable moderate and severe chron...
    Medical condition: Moderate to severe chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000010-36 Sponsor Protocol Number: M/34273/25 Start Date*: 2007-10-18
    Sponsor Name:Laboratorios Almirall, S.A.
    Full Title: A multiple dose, double-blind, double-dummy, 3 period cross-over, placebo controlled clinical trial to assess the efficacy and safety of once daily inhaled aclidinium bromide 200 µg given either in...
    Medical condition: Stable moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000207-15 Sponsor Protocol Number: 1184.24 Start Date*: 2008-02-26
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A randomised, open-label, 4-way crossover study to characterize the pharmacokinetics, safety and efficacy of tiotropium and salmeterol after inhalation of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhal...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018597-20 Sponsor Protocol Number: CNVA237A2310 Start Date*: 2010-08-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, placebo- controlled, two-period cross-over study to assess the effect of 50µg inhaled NVA237 on exercise endurance in patients with moderate to severe COPD
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018668-18 Sponsor Protocol Number: CCD-0916-PR-0032 Start Date*: 2010-06-22
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE BRONCHODILATOR EFFICACY AND SAFETY AFTER SINGLE AND REPEATED ADMINISTRATIONS OF DIFFERENT DOSES OF GLYCOPYRROLATE V...
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 08:21:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA